A Zigzag but Upward Way to Develop an HIV-1 Vaccine

Wen, Zhiping; Sun, Caijun

doi:10.3390/vaccines8030511

Cited by 5 publications

(3 citation statements)

References 130 publications

(121 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been forty years since the start of the HIV pandemic [6] and a vaccine for the disease remains unavailable. Despite decades of research into HIV-1 vaccine development, a vaccine inducing durable neutralizing immunity remains elusive [7][8][9]. Of the many different regimens tested in clinical trials, the DNA-MVA-protein regimen appears to be one of the most promising [10].…”

Section: Introductionmentioning

confidence: 99%

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

et al. 2021

View full text Add to dashboard Cite

The modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a subtype C mosaic Gag was constructed (LSDVGC5) and compared to the equivalent recombinant modified vaccinia Ankara (MVAGC5). In vitro characterization confirmed that cells infected with recombinant LSDV produced Gag virus-like particles containing Env, and that Env expressed on the surface of the cells infected with LSDV was in a native-like conformation. This candidate HIV-1 vaccine (L) was tested in a rabbit model using different heterologous vaccination regimens, in combination with DNA (D) and MVA (M) vectors expressing the equivalent HIV-1 antigens. The four different vaccination regimens (DDMMLL, DDMLML, DDLMLM, and DDLLMM) all elicited high titers of binding and Tier 1A neutralizing antibodies (NAbs), and some regimens induced Tier 1B NAbs. Furthermore, two rabbits in the DDLMLM group developed low levels of autologous Tier 2 NAbs. The humoral immune responses elicited against HIV-1 Env by the recombinant LSDVGC5 were comparable to those induced by MVAGC5.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In addition to discovering small molecule inhibitors, developing safe and effective HIV vaccines ( Wen and Sun, 2020 ), HIV CRISPR/Cas9 gene editing ( Xiao et al, 2019 ; Hashmat et al, 2020 ), and shock and kill ( Deeks, 2012 ; Abner and Jordan, 2019 ) strategies are also important treatment methods in AIDS therapy. Besides, there are other therapeutic approaches that deserve attention, such as stem cell transplantation, broad-spectrum neutralizing antibody therapy, specific T cell therapy, and traditional Chinese medicine prevention and treatment.…”

Section: Discussionmentioning

confidence: 99%

Bibliometric analysis and visualization of research trends on HIV-1 capsid inhibitors (2000–2022)

Sun,

Zhang,

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Acquired immunodeficiency syndrome (AIDS) has seriously endangered human life and health, the main pathogenic agent is human immunodeficiency virus type 1 (HIV-1). The combination antiretroviral therapy (cART) has shown serious drug resistance and side effects, and the discovery of HIV-1 capsid inhibitors is an effective way to solve the problem. Recent studies have shown significant progress in the research of HIV-1 capsid inhibitors. However, there is still a lack of comprehensive overview of bibliometric analysis in this field. This study aimed to provide the research trends and hotspots of HIV-1 capsid inhibitors.Method: Publications related to HIV-1 capsid inhibitors from 2000 to 2022 were searched on the Web of Science Core Collection (WoSCC) database and screened according to inclusion criteria. VOSviewer was conducted to evaluate the results.Results: 96 publications from 25 countries were finally included, and the number of annual publications related to HIV-1 capsid inhibitors showed an increasing trend. The United States was the most productive country with the most publication number, H-index, and total citation number, as well as the widest international cooperation. The most popular journal in this field was Journal of Virology. Drexel University was the most productive institution, and Simon Cocklin participated in the most publications. Keywords co-occurrence analysis exhibited that studying the molecular mechanism of capsid protein, discovering drug candidates, and improving antiretroviral therapy are the main and hot topics in this field.Conclusion: This is the first bibliometric study in the field of HIV-1 capsid inhibitors, which comprehensively analyzed the research trends and hotspots in this direction. This work is expected to provide the scientific community with new insights to promote the research of HIV-1 capsid inhibitors.

show abstract

“…However, the extraordinary genetic diversity, latent viral reservoirs, and lack of the immune correlates of protection against HIV-1 infection are the major challenges for developing an effective HIV-1 vaccine. So far, hundreds of HIV-1 vaccine trials have been studied, including the AIDSVAX trial (protein subunit vaccine, aimed to produce the neutralizing antibodies), STEP trial (viral vectored-HIV vaccine, aimed to elicit T-cell immune responses), and RV144 trial (combined immunization with ALVAC-HIV/AIDSVAX, aimed to induce a balanced immunity with both humoral and cellular responses) ( 3 , 4 ). Among them, the RV144 trial remains the only one to demonstrate a positive signal with an estimated efficacy of 31.2% ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Immunogenicity of HIV-1 CRF07_BC Gag Antigen With or Without a Seven Amino Acid Deletion in p6 Region

Yuan

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

HIV-1 CRF07_BC-p6Δ7, a strain with a seven amino acid deletion in the p6 region of the Gag protein, is becoming the dominant strain of HIV transmission among men who have sex with men (MSM) in China. Previous studies demonstrated that HIV-1 patients infected by CRF07_BC-p6Δ7 strain had lower viral load and slower disease progression than those patients infected with CRF07_BC wild-type strain. However, the underlying mechanism for this observation is not fully clarified yet. In this study, we constructed the recombinant DNA plasmid and adenovirus type 2 (Ad2) vector-based constructs to express the HIV-1 CRF07_BC Gag antigen with or without p6Δ7 mutation and then investigated their immunogenicity in mice. Our results showed that HIV-1 CRF07_BC Gag antigen with p6Δ7 mutation induced a comparable level of Gag-specific antibodies but stronger CD4+ and CD8+ T-cell immune responses than that of CRF07_BC Gag (07_BC-wt). Furthermore, we identified a series of T-cell epitopes, which induced strong T-cell immune response and cross-immunity with CRF01_AE Gag. These findings implied that the p6Gag protein with a seven amino acid deletion might enhance the Gag immunogenicity in particular cellular immunity, which provides valuable information to clarify the pathogenic mechanism of HIV-1 CRF07_BC-p6Δ7 and to develop precise vaccine strategies against HIV-1 infection.

show abstract

A Zigzag but Upward Way to Develop an HIV-1 Vaccine

Cited by 5 publications

References 130 publications

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV

Bibliometric analysis and visualization of research trends on HIV-1 capsid inhibitors (2000–2022)

Comparison of the Immunogenicity of HIV-1 CRF07_BC Gag Antigen With or Without a Seven Amino Acid Deletion in p6 Region

Contact Info

Product

Resources

About